Followers | 198 |
Posts | 24998 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 20, 2022 11:01:00 PM
Using the MDACC Score, predicted survival was determined for all DCVax- Direct Phase I patients and compared to actual survival (the MDACC Score was calculated from patients treated with other experimental therapies)
Outcome: 76% of evaluable patients in the DCVax-Direct trial exceeded their predicted survival time, by an average of 14.3 months*
As for survival data, and again, all of these patients had exhausted their other treatment options and were effectively on their way to hospice, and as of the 2019 ASCO presentation that Bosch gave:
3 of 25 patients still alive at 7 years.
5 of 25 patients lived > 5 years
10 of 25 patients lived > or = to approximately 3 years
Median Survival was 21.5 months
Expected mOS on SoC: 15 – 17 months
https://vimeo.com/340029244
If I can yet, I'll dig for more later.
Tumor response was a secondary measure. Primary outcome was safety.
Key exclusions:
Heavily pretreated (HP) subjects are not eligible for this study, unless treatments have occurred more than 1 year in the past.
Prior active immunotherapy for cancer within the past 2 years.
The poster on the iHub page above is not dated but does not go out as far as the 2019 chart, which goes out to 96 months with a list of patients living well beyond the Expected mOS indicated. I don't know how many are still living, but we know of at least one who has been very public about his treatment.
I believe that because it was a safety trial, they only injected one tumor, but also saw systemic immune response, though the details I do not have and that is to the best of my recollection.
All of this is IMHO, please everyone, do your own due diligence and confirm whatever I have offered from my memory and quick review.
I think the expectation is, if treated earlier, the DCVax Direct vaccine will likely do much better than this, and that with combination therapy, it is also very likely that patients would potentially be able to be studied as they are in the DCVax-L trial to understand their immune reaction and correct any immune reactions that may interfere with the effect of the treatment with checkpoint inhibitor drugs or CSF-1Ri / PLX3397.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM